skip to Main Content

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease


Brief Summary:

To evaluate the safety and tolerability of NYX-458 in mild cognitive impairments associated
with Parkinson’s disease and explore the potential benefit in cognition.


Inclusion Criteria:

– A primary diagnosis of mild cognitive impairment associated with Parkinson’s Disease

– Montreal Cognitive Assessment ≥ 17

– Modified Hoehn and Yahr Stage 1 to 3, Inclusive

– Stable anti-parkinsonian regimen

– Has a study partner who can accompany the subject at specified study visits

Exclusion Criteria:

– Clinically meaningful motor complications

– Meets criteria for dementia

– Current use of medications with primarily central nervous system activities

– Other clinically significant medical histories that may interfere with completing the


  • Aptinyx Clinical Site, Fresno, California, United States, 93710
  • Aptinyx Clinical Site, Oxnard, California, United States, 93030
  • Aptinyx Clinical Site, Pasadena, California, United States, 91105
  • Aptinyx Clinical Site, Reseda, California, United States, 91335
  • Aptinyx Clinical Site, Simi Valley, California, United States, 93065
Back To Top